Evidence map›Paper›PMID 34894233›Full record

ReviewThe international journal of neuropsychopharmacology2022

Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression.

Ethan Ponton, Gustavo Turecki, Corina Nagy

Open access · goldAbstract readReview
In one paragraph

Review in The international journal of neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Ketamine or Esketamine in Special Populations of Patients With Treatment-Resistant Depression.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.Psychedelic medicine (New Rochelle, N.Y.) · 2025
    Review
  13. Article
  14. A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ethan PontonDepartment of Anatomy and Cell Biology, McGill University, Montreal, Canada.ORCID 0000-0002-4891-4800
Gustavo TureckiMcGill Group for Suicide Studies, Douglas Mental Health University Institute, Montreal, Canada.
Corina NagyMcGill Group for Suicide Studies, Douglas Mental Health University Institute, Montreal, Canada.ORCID 0000-0003-1439-0129
Douglas Mental Health University Institute · CAMcGill University · CA

Funding

Canadian Institute of Health Research FDN148374
6 · The paper itself

Abstract

Major depressive disorder (MDD) is a common psychiatric illness that manifests in sex-influenced ways. Men and women may experience depression differently and also respond to various antidepressant treatments in sex-influenced ways. Ketamine, which is now being used as a rapid-acting antidepressant, is likely the same. To date, the majority of studies investigating treatment outcomes in MDD do not disaggregate the findings in males and females, and this is also true for ketamine. This review aims to highlight that gap by exploring pre-clinical data-at a behavioral, molecular, and structural level-and recent clinical trials. Sex hormones, particularly estrogen and progesterone, influence the response at all levels examined, and sex is therefore a critical factor to examine when looking at ketamine response. Taken together, the data show females are more sensitive to ketamine than males, and it might be possible to monitor the phase of the menstrual cycle to mitigate some risks associated with the use of ketamine for females with MDD. Based on the studies reviewed in this article, we suggest that ketamine should be administered adhering to sex-specific considerations.

Indexed as

Sex CharacteristicsAntidepressive AgentsFemaleHumansKetamineMajor Depressive DisorderMaleAntidepressive AgentsKetamineBDNFcytochromeslow-dose ketaminerapid-acting antidepressantssexual dimorphism

Identifiers

PMID34894233
PMCPMC8756094
OpenAlexW4200250750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.